Y-mAbs Therapeutics, Inc (NASDAQ:YMAB)
| 32.97 Delayed Data As of Jan 17 |  +0.35 / +1.07%Today’s Change | 18.60 Today|||52-Week Range 34.49 | +5.50% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.3B |
Company Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Contact Information
Y-mAbs Therapeutics, Inc. 230 Park Avenue New York New York 10169 |
Employees
Shareholders
| Individual stakeholders | 28.99% |
| Mutual fund holders | 26.12% |
| Other institutional | 2.14% |
Top Executives
| There are no executives to display. |
